New research has demonstrated the potential for the ADDomer ™ platform to produce thermostable vaccines and reagents to tackle viral infections The study was led by the University of Bristol and Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer platform. 

The research team explored the innovative technology behind the development of an ADDomer vaccine targeting severe acute respiratory syndrome COVID-19 (SARS-CoV-2). The study, using an integrated approach, combined synthetic, computational and structural methods with in vitro antibody selection and in vivo immunisation to design, produce and validate nature-inspired nanoparticle-based vaccines and reagents.

 The research demonstrates the use of Imophoron’s patented multivalent nanoparticle superbinder technology against SARS-CoV-2, including immune-evasive variants of concern. 

Read the full University of Bristol news item

'In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2' by Imre Berger et al. in Antibody Therapeutics [open access]